Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
October 8, 2026

Avutometinib plus defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer as of October 2026

MARA Rating Company October 8, 2026

Zidesamtinib / Jideytro for Previously Treated ROS1-Positive Metastatic Non-Small Cell Lung Cancer as of October 2026

MARA Rating Company October 8, 2026

Ziihera / Zanidatamab for First-Line HER2-Positive Gastroesophageal Adenocarcinoma as of October 2026

MARA Rating Company October 8, 2026

Tudriqev / Vusolimogene oderparepvec for Advanced Melanoma as of October 2026

MARA Rating Company October 8, 2026

Lumvoa / Veligrotug for Thyroid Eye Disease as of October 2026

MARA Rating Company October 8, 2026

Daybue / Trofinetide for Rett Syndrome as of October 2026

MARA Rating Company October 8, 2026

Mimrylo / Rusfertide for Polycythemia Vera as of October 2026

MARA Rating Company October 8, 2026

Nezglyal / Leriglitazone for Cerebral Adrenoleukodystrophy as of October 2026

MARA Rating Company October 8, 2026

Tregzi for Matched-Donor Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Hematological Malignancies as of October 2026

MARA Rating Company October 8, 2026

Zenbexus / Iberdomide for Relapsed or Refractory Multiple Myeloma, Second Line or Later, in Combination With Daratumumab and Dexamethasone as of October 2026

MARA Rating Company October 8, 2026